News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
All Stories
News
Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics
October 6, 2023
San Francisco Business Times
Read Now
Press Release
Influential Women 2023: Svetlana Lucas, Chief Business Officer, Scribe Therapeutics
October 6, 2023
San Francisco Business Times
Read Now
News
This Scientist Is Building Custom Gene-Editing Tools
July 25, 2023
Forbes
Read Now
Press Release
This Scientist Is Building Custom Gene-Editing Tools
July 25, 2023
Forbes
Read Now
News
Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners
July 20, 2023
Wall Street Journal
Read Now
Press Release
Scribe Therapeutics' Gene-Editing Tech Attracts Pharma Partners
July 20, 2023
Wall Street Journal
Read Now
News
Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease
July 18, 2023
BioWorld
Read Now
Press Release
Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease
July 18, 2023
BioWorld
Read Now
News
Sanofi expands collaboration with Scribe on CRISPR genome editing
July 18, 2023
Seeking Alpha
Read Now
Press Release
Sanofi expands collaboration with Scribe on CRISPR genome editing
July 18, 2023
Seeking Alpha
Read Now
News
East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease
July 18, 2023
San Francisco Business Times
Read Now
Press Release
East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease
July 18, 2023
San Francisco Business Times
Read Now